JOP20220174A1 - دايمر il-15 غير المتجانس المعبر عنه بواسطة الخلية cho - Google Patents

دايمر il-15 غير المتجانس المعبر عنه بواسطة الخلية cho

Info

Publication number
JOP20220174A1
JOP20220174A1 JOP/2022/0174A JOP20220174A JOP20220174A1 JO P20220174 A1 JOP20220174 A1 JO P20220174A1 JO P20220174 A JOP20220174 A JO P20220174A JO P20220174 A1 JOP20220174 A1 JO P20220174A1
Authority
JO
Jordan
Prior art keywords
cho cell
heterologous
dimer expressed
dimer
expressed
Prior art date
Application number
JOP/2022/0174A
Other languages
English (en)
Inventor
Thomas Jostock
Alexandre Aurélien Pons
Justyna Jozefczuk
Richard Gabriel
Urs Ulrich Lohrig
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20220174A1 publication Critical patent/JOP20220174A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع الحالي بدايمر IL-15/IL-15R? غير متجانس تم إنتاجه في سلالة الخلية CHO، وطريقة إنتاج الدايمر غير المتجانس وطريقة علاج باستخدام الدايمر غير المتجانس.
JOP/2022/0174A 2020-02-05 2022-07-25 دايمر il-15 غير المتجانس المعبر عنه بواسطة الخلية cho JOP20220174A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062970485P 2020-02-05 2020-02-05
PCT/IB2021/050730 WO2021156720A1 (en) 2020-02-05 2021-01-29 Cho cell expressing il-15 heterodimers

Publications (1)

Publication Number Publication Date
JOP20220174A1 true JOP20220174A1 (ar) 2023-01-30

Family

ID=74554194

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0174A JOP20220174A1 (ar) 2020-02-05 2022-07-25 دايمر il-15 غير المتجانس المعبر عنه بواسطة الخلية cho

Country Status (22)

Country Link
US (1) US20210244821A1 (ar)
EP (1) EP4100425A1 (ar)
JP (2) JP2022522566A (ar)
KR (1) KR20220137651A (ar)
CN (1) CN115023436A (ar)
AR (1) AR121261A1 (ar)
AU (1) AU2021215893A1 (ar)
BR (1) BR112022014493A2 (ar)
CA (1) CA3168469A1 (ar)
CL (2) CL2022002094A1 (ar)
CO (1) CO2022010860A2 (ar)
CR (1) CR20220367A (ar)
DO (1) DOP2022000156A (ar)
EC (1) ECSP22060286A (ar)
IL (1) IL295278A (ar)
JO (1) JOP20220174A1 (ar)
MX (1) MX2022009611A (ar)
PE (1) PE20221509A1 (ar)
PH (1) PH12022552029A1 (ar)
TW (1) TWI893058B (ar)
UY (1) UY39062A (ar)
WO (1) WO2021156720A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022090203A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
EP4232068A1 (en) 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
WO2024097918A1 (en) 2022-11-04 2024-05-10 Novartis Ag Nkg2d fusion protein cancer therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
US8021668B2 (en) 2005-12-12 2011-09-20 Immune Disease Institute, Inc. Integrin alpha L I domain mutants with increased binding affinity
NZ569541A (en) * 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
CN101743249B (zh) * 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
CA2727953C (en) 2008-08-22 2017-05-16 Magna Seating Inc. Disc recliner with reduced backlash
MY159849A (en) * 2008-12-22 2017-02-15 Lek Pharmaceuticals Mammalian expression vector
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
US8507222B2 (en) * 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
US20130243744A1 (en) * 2011-01-06 2013-09-19 Michael J. Betenbaugh Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells
US20150359853A1 (en) * 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
PL3137595T3 (pl) * 2014-04-29 2019-09-30 Novartis Ag Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania
EP3015475A1 (en) * 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
PL3235830T3 (pl) * 2014-12-19 2020-12-14 Jiangsu Hengrui Medicine Co., Ltd. Kompleks białkowy interleukiny 15 i jego zastosowanie
EP3390643B8 (en) * 2015-12-18 2023-08-02 OncoSec Medical Incorporated Plasmid constructs for heterologous protein expression and methods of use
ES2972406T3 (es) * 2016-08-01 2024-06-12 Virogin Biotech Canada Ltd Vectores del virus oncolítico del herpes simple que expresan moléculas estimuladoras del sistema inmunitario
MY203000A (en) * 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
EP4613776A3 (en) * 2016-10-21 2025-11-26 Altor BioScience Corporation Multimeric il-15-based molecules
WO2018134782A1 (en) * 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
WO2019150310A1 (en) * 2018-02-02 2019-08-08 Novartis Ag Combination of sting agonist and il-15/il15-ra for the treatment of cancer
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15

Also Published As

Publication number Publication date
MX2022009611A (es) 2022-11-07
IL295278A (en) 2022-10-01
CN115023436A (zh) 2022-09-06
TWI893058B (zh) 2025-08-11
CR20220367A (es) 2022-08-30
PE20221509A1 (es) 2022-10-04
JP2023145622A (ja) 2023-10-11
JP2022522566A (ja) 2022-04-20
CL2023002447A1 (es) 2024-03-15
BR112022014493A2 (pt) 2022-09-20
EP4100425A1 (en) 2022-12-14
CA3168469A1 (en) 2021-08-12
AR121261A1 (es) 2022-05-04
DOP2022000156A (es) 2022-10-16
KR20220137651A (ko) 2022-10-12
CO2022010860A2 (es) 2022-08-19
AU2021215893A1 (en) 2022-08-25
CL2022002094A1 (es) 2023-03-10
TW202142558A (zh) 2021-11-16
WO2021156720A1 (en) 2021-08-12
PH12022552029A1 (en) 2023-11-20
US20210244821A1 (en) 2021-08-12
UY39062A (es) 2021-09-30
ECSP22060286A (es) 2022-09-30

Similar Documents

Publication Publication Date Title
JOP20220174A1 (ar) دايمر il-15 غير المتجانس المعبر عنه بواسطة الخلية cho
ZA202402511B (en) Compositions and methods for producing circular polyribonucleotides
PH12021550676A1 (en) Plant inoculation method
PH12020550529A1 (en) Recombinant bacterium capable of producing l-lysine, construction method thereof and production method of l-lysine
MX395019B (es) Catalizador electroquimico para la conversion de co2 en etanol.
CO2019008826A2 (es) Celulas microbianas, metodos para producir las mismas, y usos de las mismas
MY201960A (en) Method for obtaining alcohols from aldehydes ii
BR112022001207A2 (pt) Método de obtenção de mitocôndrias de células e mitocôndrias obtidas
EA202091906A1 (ru) Предотвращение или уменьшение роста растений путем биоцементации
EA202091021A1 (ru) Способ получения водных растворов полиакриламида
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
MX2024007870A (es) Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
JOP20230038A1 (ar) طرق واستخدامات لإنتاج تركيبات تشتمل بصورة ثابتة على أنواع من الكلور الحر المتاح وبيروكسيدات
TR201914501A2 (tr) Aeroponi̇k i̇ç ortam bi̇tki̇ yeti̇şti̇rme modülleri̇
MX2016002651A (es) Microorganismo modificado para la produccion mejorada de alanina.
UY37932A (es) Proceso para producir compuestos de piridazinona herbicidas
MX2019009214A (es) Microorganismo del genero corynebacterium que produce 5'-xantosina monofosfato y procedimiento de preparacion de 5'-xantosina monofosfato mediante el uso del mismo.
CO2020002617A2 (es) Método para la producción de plántulas de caña de azúcar
MX2021012454A (es) Cromosoma artificial recombinante y su uso.
MX2021015045A (es) Construcciones de unión biespecíficas.
MX2024000077A (es) Metodo.
TR202107256A2 (tr) Bor katkili tuz
PL442396A1 (pl) Turbina pionowa napędzana siłą wiatru
MX2023014870A (es) Nueva variante de mdth y metodo para producir o-fosfoserina, cisteina, y sus derivados usando la misma.
PL429525A1 (pl) Zastosowanie szkła wodnego